Oncogenic potential of human papillomavirus (HPV) and its relation with cervical cancer

Virology Journal

Volumn 8, Issue , 2011, Pages

  Faridi, Rabia ^a   Zahra, Amreen ^a   Khan, Khalida ^a   Idrees, Muhammad ^a  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ORAL CONTRACEPTIVE AGENT; VIRUS DNA; WART VIRUS VACCINE;

CANCER RISK; COLPOSCOPY; CONDYLOMA ACUMINATUM; DISEASE COURSE; HORMONE SUBSTITUTION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; INCIDENCE; NONHUMAN; OUTCOME ASSESSMENT; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PREVALENCE; REVIEW; SEXUAL BEHAVIOR; SMOKING; SPERM; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS CARCINOGENESIS; VIRUS LIKE AGENT; VIRUS MORPHOLOGY; VIRUS PATHOGENESIS; VIRUS REPLICATION; CLASSIFICATION; FEMALE; ISOLATION AND PURIFICATION; PAPILLOMA VIRUS; PATHOGENICITY; RISK FACTOR; UTERINE CERVIX TUMOR; VIROLOGY;

HUMAN PAPILLOMAVIRUS;

FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 79957801393     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-269     Document Type: Review

References (85)

1. Review of Medical Microbiology and Immunology, Mc GrawHill, Warren Levinson, 10 2008 270 275
2. Molecular biologists for Oncologists, Chapman and Hall, Yarnold JR, Stratton MR, McmMillan TJ, 2 1996 83 88
3. Human papillomavirus subtype 16 is common in Pakistaniwomen with cervical carcinoma. S Khan NN Jaffer MN Khan MA Rai M Shafiq A Ali S Pervez N Khan A Aziz SH Ali, Int J Infect Dis 2007 11 313 317 10.1016/j.ijid.2006.06.007 17291804 (Pubitemid 46990965)
4. 7oncoproteins of High-risk HPV. A Yasmeen A Alachkar H Dekhil C Gambacorti-Passerini AE Al Moustafa, J Oncol 2010 2010 10
5. Seroprevalence of human papillomavirus type16 infection in the United States. MK Stone LK Karem RM Sternberg MG McQuillan DA Poon RA Unger CW Reeves, J Infect Dis 2002 186 1396 1402 10.1086/344354 12404154
6. Determinants of Seropositivity among HPV16/18DNA positive young women. C Porass C Bennett M Safaeian S Coseo AC Rodriguez P Gonzaález M Hutchinson S Jimenez ME Sherman S Wacholder D Solomon V Doorn Leen-Jan C Bougelet W Quint M Schiffman R Herrero A Hildeshein, BMC Infect Dis 2010 10 238 20698998
7. Tissue-spanning redox gradient-dependant assembly of native human papilloma virus type 16 virions. MJ Conway S Alam EJ Ryndock L Cruz ND Christensen RBS Roden C Meyers, J virol 2009 83 10515 10526 10.1128/JVI.00731-09 19656879
8. Microbiology and molecular biology reviews. 2004 68 2 1092 2172
9. 5- induced cell fusion a critical initiating event in the early stage of HPV-associated cervical cancer. P Gao J Zheng, J Virol 2010 7 238 10.1186/1743-422X-7-238
10. Basic mechanisms of High-risk human papilloma virus induced carcinogenesis. M Nariseuva Saito,, et al. Cancer Science 2007 98 1505 1511 10.1111/j.1349-7006.2007.00546.x 17645777
11. 5protein. TC Tsai SL Chen, Archieves Virology 2003 148 1445 1453 10.1007/s00705-003-0111-z (Pubitemid 36990289)
12. 7through sequences necessary for transformation. D Zerfass,, et al. J Virol 1995 69 6389 6399 7666540
13. 2protein is inhibited by overexpression of bromodomain containing protein 4. D Gagnon S Joubert H Senechal A Fradet-Turcotte S Torre J Archambault, J Virol 2009 83 4127 4139 10.1128/JVI.02468-08 19211738
14. 6protein of the cutaneous human papillomavirus type 8 can stimulate the viral early and late promoters by distinct mechanisms. A Muller Schiffmann J Beckmann G Steger, J Virol 2006 80 8718 8728 10.1128/JVI.00250-06 16912319 (Pubitemid 44384881)
15. 2gene product of human papillomavirus type 16 represses early transcription of replication but is dispensable for viral plasmid persistence in Keratinocytes. MJ Lace JR Anson GS Thomas LP Turek TH Haugen, J Virol 2008 82 10841 10853 10.1128/JVI.01481-08 18753207 (Pubitemid 352691200)
16. 6. A Incassati D Patel DJ McCance, Oncogene 2006 25 2444 2451 10.1038/sj.onc.1209276 16369493
17. 7requires the protease calpain to degrade the retinoblastoma protein. GA Darnell WA Schroder TM Antalis E Lambley L Major J Gardner G Birell A Suhrbier, J Biol Chem 2007 282 37492 37500 10.1074/jbc.M706860200 17977825
18. 7proteins of low and high-risk human papilloma viruses share the ability to target the pRb family member p130 for degradation. B Zhang W Chen A Roman, Proc Natl Acad Sci 2006 103 437 442 10.1073/pnas.0510012103 16381817 (Pubitemid 43122419)
19. 7oncoprotein is able to bind to the retinoblastomagene product. N Dyson PM Howley M K E Harlow, Science 1987 243 934 937 (Pubitemid 19066153)
20. Human papillomavirus type distribution in invasive cervical cancer and high-grdae cervical lesions:a meta analysis update. JS Smith L Lindsay B Hoots J Keys S Franceschin R Winer GM Clifford, Int J Cancer 2007 3 621 632 (Pubitemid 46986496)
21. Immune responses to human papillomavirus. M Stanely, Vaccine 2006 24 suppl1 10 16
22. Relation ship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma. EM de Villiers, Int J Cancer 2003 103 705 708 10.1002/ijc.10868 12516087
23. Sensitivity of the cervical transformation zone to estrogen induced squamous carcinogenesis. DA Elson RR Riley A Lacey G Thordarson FJ Talamantes JM Arbeit, Cancer Research 2000 60 1267 1275 10728686 (Pubitemid 30151994)
24. Estradiol enhances human B cell maturation via inhibition of suppressor T cells in pokeweed mitogen stimulated cultures. T Paavonen LC Andersson H Adlercreutz, J E M 1981 154 1935 1945 10.1084/jem.154.6.1935 (Pubitemid 12205598)
25. Regulation of Dendritic cells by female sex steroids: relevance to immunity and auto immunity. GC Hughes EA Clark, Auto immunity 2007 40 470 481 (Pubitemid 47343359)
26. Biological and clinical significance of haptoglobin in human. MR Langlois JR Delanghe, Eur J Clin Chem 1996 42 1589 1600 (Pubitemid 26354735)
27. Haptoglobin inflammation and disease. IK Quaye, Trans R soc trop medi hyg 2008 102 735 742 10.1016/j.trstmh.2008.04.010
28. Haptoglobin polymorphisms and iron homeostasis in health and in disease. HV Vilerberghe M Langlois J Delanghe, Clin chimica Acta 2004 345 35 42 10.1016/j.cccn.2004.03.016 (Pubitemid 38749169)
29. Haptoglobim genotype modulates the balance of Th1/Th2 cytokines produced by macrophages exposed to free haemoglobin. J Guetta M Strauss NS Levy L Fahoum AP Levy, Artherosclerosis 2007 191 48 53 10.1016/j.atherosclerosis.2006.04.032 (Pubitemid 46227428)
30. Haptoglobin genotype and natural fertility in humans. N Bottini A Gimelfarb F Gloria-Bottini M La Torre P Lucarelli N Lucarini, Fertility and a Sterility 1999 72 293 296 10.1016/S0015-0282(99)00210-1 (Pubitemid 29364626)
31. Prevalence of HPV infection among men: Asystematic review of the literature. EF Dunne CM Nielson KM Stone LE Markowitz AR Giuliano, J infect dis 2006 1994 1044 1057 (Pubitemid 44547644)
32. Natural history of human papillomavirus type 16 virus like particle antibodies in young women. YF Ho Gloria YY Studentsov R Bierman R D Burk, Cancer Epidemiology, Biomarkers and Prevention 2004 13 110 116 10.1158/1055-9965.EPI- 03-0191 14744741 (Pubitemid 38116628)
33. The carcinogenicity of human papillomavirus types reflects viral evolution. M Schiffman R Herrero R Desalle A Hildesheim S Wacholder AC Rodriguez MC Bratti ME Sherman J Morales D Guillen M Alfaro M Hutchinson TC Wright D Solomon Z Chen J Schussler PE Castle RD Burk, Virology 2005 337 76 84 10.1016/j.virol.2005.04.002 15914222 (Pubitemid 40725441)
34. Prevalence of human papillomavirus infection in women in Busan, South Korea. HR Shin DH Lee R Herrero JS Smith S Vaccarella SH Hong KY Jung HH Kim UD Park HS Cha S Park A Touzé N Mũoz PJ Snijders CJ Meijer P Coursaget S Franceschi, Int J Cancer 2003 103 413 421 10.1002/ijc.10825 12471626 (Pubitemid 36076436)
35. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Mũoz FX Bosch S de Sanjosé R Herrero X Castellsagué KV Shah PJ Snijders CJ Meijer, New Eng J Med 2003 348 518 527 10.1056/NEJMoa021641 12571259 (Pubitemid 36159887)
36. 6protein of the cutaneous human papillomavirus type 8 can stimulate the viral early and late promoters by distinct mechanism. A Müller-Schiffmann J Beckmann J Steger, J virol 2006 80 8718 8728 10.1128/JVI.00250-06 16912319 (Pubitemid 44384881)
37. Interferon-{beta}treatment of cervical keratinocytes naturally infected with human papillomavirus16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. MT Herdman MR Pett I Roberts WO Alazawi AE Teschendorff XY Zhang MA Stanley N Coleman, Carcinogenesis 2006 27 2341 2353 10.1093/carcin/bgl172 16973673 (Pubitemid 44644825)
38. The casual relationship between human papillomavirus and cervical cancer. FX Bosch A Lorincz N Mũoz CJ Meijer KV Shah, J clin Pathol 2002 55 4 244 265 10.1136/jcp.55.4.244 11919208 (Pubitemid 34293391)
39. Interaction of human papillomavirus with the host immune system:a well evolved relationship. IH Frazer, Virology 2009 384 2 410 414 10.1016/j.virol.2008.10.004 18986661
40. 7requires the protease Calpain to degrade the Retinoblastoma Protein. GA Darnell WA Schroder TM Antalis E Lambley L Major J Gardner G Birrell A Cid-Arregui A Suhrbier, J Bio Chem 2007 282 37492 37500 10.1074/jbc.M706860200
41. 7protein. DR Patrick A Oliff DC Heimbrook, J Bio Chem 1994 269 9 6842 6850 (Pubitemid 24191078)
42. Estrogen and ER-:Culprits in cervical cancer. SH Chung S Franceschi PF Lambert, The Cell 2010 21 504 511
43. collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. International Collaboration of Epidemiological studies of cervical cancer cervical carcinoma and reproductive factors, Int J Cancer 2006 119 1108 112 16570271
44. Cervical cancer and hormonal contraceptives:collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. International Collaboration of Epidemiological Studies of Cervical Cancer P Appleby V Beral A Berrington de González D Colin S Franceschi A Goodhill J Green J Peto M Plummer S Sweetland, Lancet 2007 370 1609 1621 17993361
45. Cancer incidence in five continents. MP Curado BK Edward HR Shin H Storm, 29th Meeting of the International Association of Cancer Registries. 2007 September 17. Ljubliana, Slovenia
46. Chronic inflammation, immunosupression in cancer:new insights and outlook. M Baniyash, Seminar cancer biology 2006 16 1 80 88 10.1016/j.semcancer. 2005.12.002 (Pubitemid 43139712)
47. Seminal plasma differentially regulates inflammatory cytokine gene expreesion in human cervical and vaginal epithelial cells. DJ Sharkey AM Macpherson KP Tremellen SA Robertson, Mol hum rep 2007 13 7 491 501 10.1093/molehr/gam028 (Pubitemid 47062888)
48. Immunosuppressive mechanism in semen: Implications for contraceptions. RW Kelly, Hum Rep 1995 10 7 1686 1693
49. Seminal plasma activates cyclooxygenase-2 and prostaglandin E2 receptor expression and signalling in cervical adenocarcinoma cells. KJ Sales AA Katz RP Millar HN Jabbour, Mol Hum Rep J 2002 8 12 1065 1070 10.1093/molehr/8.12.1065 (Pubitemid 36032843)
50. High expression of PGE2 enzymatic pathways in cervical (Pre) neoplastic lesions and functional consequences for antigen-presenting cells. M Herfs L Herman P Hubert F Minner M Arafa P Roncarati Y Henrotin J Boniver P Delvenne, Cancer Immunology J 2009 58 4 603 614
51. Effects of environmental tobacco smoke in vivo on rhesus monkey semen quality, sperm function, sperm metabolism. PH Hung L Froenicke CY Lin LA Lyons MG Miller KE Pinkerton CA VandeVoort, Reproductive Toxicology 2009 27 2 140 14 10.1016/j.reprotox.2008.12.007 19159676
52. Human papillomavirus and cervical cancer. M Schiffman EP Castle J Jeronimo AC Rodriguez S Wacholder, Lancet 2007 370 9590 890 907 10.1016/S0140-6736(07)61416-0 17826171 (Pubitemid 47371147)
53. Sexual behaviour in context:a global perspective. K Wellings M Collumbien E Slaymaker S Singh Z Hodges D Patel N Bajo, Lancet 2006 368 9548 1706 1728 10.1016/S0140-6736(06)69479-8 17098090 (Pubitemid 46055217)
54. Comprehensive study of several general and type specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin embedded cervical carcinomas. MF Baay WG Quint J Koudstaal H Hollema JM Duk MP Burger E Stolz P Herbrink, J Clin Microbiol 1996 34 745 747 8904451 (Pubitemid 26065812)
55. Highly effengtive detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad spectrum and type specific PCR. LJ Van Doorn A Molijn B Kleter W Quint B Colau, J Clin Microbiol 2006 44 3292 3298 10.1128/JCM.00539-06 16954263 (Pubitemid 44413767)
56. Determinants of HPV types 16,18 infections in the lower female genital tract in an Italian population. A Venuti G Badaracco A Sedati R Carbini ML Marcante, Eur J Gynaecol Oncol 2004 15 205 10
57. Prevalence and predictors of HPV infection in women in Ontario, Canada. Survey of HPV in Ontario women (SHOW) Group. JW Sellors JB Mahony J Kaczorowski A Lytwyn H Bangura S Chong A Lorincz DM Dalby V Janjusevic JL Keller, Can Med Assosc J 2000 163 503 508
58. Incidence, Clearannce and predictors of human pappilomavirus infection in women. JW Sellors TL Karwalajtys J Kaczorowski JB Mahony A Lytwyn S Chong J Sparrow A Lorincz Survey of HPV in Ontario Women Group, Can Med Assosc J 2003 168 421 425 (Pubitemid 36255727)
59. A case-control study of risk factors for invasive cervical cancer among US women exposed to oncogenic types of human pappilomavirus. TS Shields LA Brinton RD Burk SS Wang SJ Weinstein RG Ziegler YY Studentsov M McAdams M Schiffman, Cancer Epidemiology Biomarkers 2004 13 1574 1582 (Pubitemid 39331877)
60. Sexual bahaviour, condom use, and human pappilomavirus: Pooled analysis of the IARC human pappilomavirus prevalence surveys. S Vaccarella S Franceschi R Herrero N Mũoz PJ Snijders GM Clifford JS Smith E Lazcano-Ponce S Sukvirach HR Shin S de Sanjosé M Molano E Matos C Ferreccio PT Anh JO Thomas CJ Meijer IARC HPV Prevalence Surveys Study Group, Cancer Epidemiology Biomarkers 2006 15 326 333 10.1158/1055-9965.EPI-05-0577 (Pubitemid 43342183)
61. Risk factors for human papillomavirus exposure and co factors for cervical cancer in Latin America and the Caribbean. M Almonte G Albero M Molano C Carcamo PJ García G Pérez, Vaccine 2008 26 16 L36 18945400
62. Reducing patient risk for human papillomavirus infection and cervical cancer. J Herbert J Coffin, J Am Osteopathic Assoc 2008 108 65 70 (Pubitemid 351340756)
63. Sexual behaviour and HPV infections in 18 to 29 year old women in the pre vaccine era in the Netherlands. CH Lenselink WJ Melchers WG Quint AM Hoebers JC Hendriks LF Massuger RL Bekkers, PLos One 2008 3 3743 10.1371/journal.pone. 0003743
64. Epidemilogical risk profile of infection with different groups of HPV. PK Chan WC Ho MC Wong AR Chang JS Chor MY Yu, J Med Virology 2009 81 1635 1644 10.1002/jmv.21575
65. Estrogen receptors and human disease. BJ Deroo KS Korach, J Clin Invest 2006 116 561 570 10.1172/JCI27987 16511588 (Pubitemid 43326860)
66. Classification of papillomaviruses. EM deVilliers, J Virology 2004 324 17 27 10.1016/j.virol.2004.03.033 (Pubitemid 38737395)
67. Immune responses to human pappilomavirus. M Stanley, Vaccine 2006 S 16 22
68. Epidemiologic profile of type specific human pappilomavirus infection and cervical neoplasia in Guanacaste, costa Rica. R Herrero PE Castle M Schiffman MC Bratti A Hildesheim J Morales M Alfaro ME Sherman S Wacholder S Chen AC Rodriguez RD Burk, J Infect Dis 2005 191 1796 807 10.1086/428850 15871111 (Pubitemid 40705385)
69. Risk factors for HPV DNA detection in middleaged women. N Mũoz I Kato FX Bosch J Eluf-Neto S De Sanjosé N Ascunce M Gili I Izarzugaza P Viladiu MJ Tormo P Moreo LC Gonzalez L Tafur JM Walboomers KV Shah, Sexually Transmitted Diseases 1996 23 504 10 10.1097/00007435-199611000-00012 8946637 (Pubitemid 26391576)
70. Prevalence of HPV infection among men: a systematic review of the literature. EF Dunne CM Nielson KM Stone LE Markowitz AR Giuliano, J Infect Dis 2006 194 1044 57 10.1086/507432 16991079 (Pubitemid 44547644)
71. A practitioner's guide to understanding immunity to human papillomavirus. M Stanley, Am J Obstet Gynecol 2009 4 2 7
72. Efficacy of a bivalent L1 virus like particle vaccine in prevention of infection with HPV types 16 and 18 in young women: A randomized controlled trial. DM Harper EL Franco C Wheeler DG Ferris D Jenkins A Schuind T Zahaf B Innis P Naud NS De Carvalho CM Roteli-Martins J Teixeira MM Blatter AP Korn W Quint G Dubin GlaxoSmithKline HPV Vaccine Study Group, Lancet 2004 364 1757 1765 10.1016/S0140-6736(04)17398-4 15541448 (Pubitemid 39488060)
73. Sustained efficacy upto 4.5 years of a bivalent L1 virus like particle vaccine against HPV types 16 and 18: Follow up from a randomized controlled trial. DM Harper EL Franco CM Wheeler AB Moscicki B Romanowski CM Roteli-Martins D Jenkins A Schuind SA Costa Clemens G Dubin HPV Vaccine Study group, Lancet 2006 367 1247 1255 10.1016/S0140-6736(06)68439-0 16631880
74. Prophylactic quadrivalent human papillomavirus (types 6,11,16 and 18) L1 virus like particle vaccine in young women:A randomised double blind placebo-controlled multicentre phase II efficacy trial. LL Villa RL Costa CA Petta RP Andrade KA Ault AR Giuliano CM Wheeler LA Koutsky C Malm M Lehtinen FE Skjeldestad SE Olsson M Steinwall DR Brown RJ Kurman BM Ronnett MH Stoler A Ferenczy DM Harper GM Tamms J Yu L Lupinacci R Railkar FJ Taddeo KU Jansen MT Esser HL Sings AJ Saah E Barr, Lancet 2005 6 271 278 10.1016/S1470-2045(05) 70101-7
75. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow up. LL Villa RL Costa CA Petta RP Andrade J Paavonen OE Iversen SE Olsson J Høye M Steinwall G Riis-Johannessen A Andersson-Ellstrom K Elfgren G Krogh M Lehtinen C Malm GM Tamms K Giacoletti L Lupinacci R Railkar FJ Taddeo J Bryan MT Esser HL Sings AJ Saah E Barr, Br J Cancer 2006 95 1459 1466 10.1038/sj.bjc.6603469 17117182 (Pubitemid 44863348)
76. Efficay of human papillomavirus (HP oncogenic HPV types (PATRICIA): Final analysis of a double-blind randomised study in young women. J Paavonen P Naud J Salmerán CM Wheeler SN Chow D Apter H Kitchener X Castellsague JC Teixeira SR Skinner J Hedrick U Jaisamrarn G Limson S Garland A Szarewski B Romanowski FY Aoki TF Schwarz WA Poppe FX Bosch D Jenkins K Hardt T Zahaf D Descamps F Struyf M Lehtinen G Dubin HPV PATRICIA Study Group M Greenacre, Lancet 2009 374 301 314 10.1016/S0140-6736(09)61248-4 19586656
77. Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands. AB Bos M Rebolj JD Habbema M van Ballegooijen, Int J Cancer 2006 119 2372 5 10.1002/ijc.22114 16858676 (Pubitemid 44546958)
78. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. AG Bais FJ van Kemenade J Berkhof RH Verheijen PJ Snijders F Voorhorst M Babov M van Ballegooijen TJ Helmerhorst CJ Meijer, Int J Cancer 2007 120 1505 10 10.1002/ijc.22484 17205514 (Pubitemid 46355385)
79. Cervical cancer screening programme in Finland with an example on implementing alternative screening methods. A Anttila P Nieminen, Collegium Antropologicum 2007 31 17 22 17600933
80. Cervical cancer screening programmes and policies in 18 European countries. A Anttila G Ronco G Clifford F Bray M Hakama M Arbyn E Weiderpass, Br J Cancer 2004 91 935 41 15280916 (Pubitemid 39273788)
81. Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. M Van Ballegooijen E van den Akker-van Marle J Patnick E Lynge M Arbyn A Anttila G Ronco J Dik F Habbema, Eur Journal of Can 2000 36 2177 88 10.1016/S0959-8049(00)00330-0
82. The cervical cancer epidemic that screening has prevented in the UK. J Peto C Gilham O Fletcher FE Matthews, Lancet 2004 364 249 56 10.1016/S0140-6736(04)16674-9 15262102 (Pubitemid 38942814)
83. New technologies in cervical cytology screening: a word of caution. GF Sawaya DA Grimes, Obstet Gynecol 1999 94 307 10 10.1016/S0029-7844(99)00289-6 10432148 (Pubitemid 29352882)
84. Missed opportunities for cervical cancer screening of HMO members developing invasive cervical cancer (ICC). W Kinney HY Sung KA Kearney M Miller G Sawaya RA Hiatt, Gynecol Oncol 1998 71 428 30 10.1006/gyno.1998.5135 9887244 (Pubitemid 29022332)
85. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. PD Sasieni J Cuzick E Lynch-Farmery, Br J Cancer 1996 73 1001 5 10.1038/bjc.1996.196 8611418 (Pubitemid 26116757)